H.R. 1313House118th Congress (2023-2025)In Committee

Transparency in CFPB Cost-Benefit Analysis Act

To enhance rulemaking requirements for the Bureau of Consumer Financial Protection, and for other purposes.

Introduced March 1, 2023

AI-Generated Summary

Updated January 20, 2026 at 4:13 AM UTC

The Transparency in CFPB Cost‑Benefit Analysis Act amends the Consumer Financial Protection Act to require the CFPB to provide much more detailed information when proposing new regulations. It forces the agency to publish a full notice in the Federal Register that explains the need for the rule, why the market or other governments can’t address the issue, and a thorough cost‑benefit analysis. The rule applies to the CFPB, the entities it regulates, small businesses, and state, local and tribal governments.

Key Provisions

  • Require each CFPB notice of proposed rulemaking to be published in full in the Federal Register
  • Include a statement of why the regulation is needed and why non‑federal actors cannot solve the problem
  • Identify any duplication or conflict with existing federal rules and explain how the new rule is justified or can coexist
  • Provide a quantitative and qualitative assessment of all direct and indirect costs and benefits, including compliance costs, economic impacts, and costs to state, local and tribal entities
  • Identify reasonable alternative approaches and analyze their costs and benefits
  • If the rule would raise costs for small businesses, the CFPB must consult the SBA Office of Advocacy to seek ways to lessen the impact
  • Require justification when net benefits of the proposed rule are lower than those of alternatives or when costs exceed benefits
  • Disclose underlying assumptions, data sources, and whether studies used were peer‑reviewed, and, when feasible, include probability distributions of expected outcomes

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
HouseIntro Referral Latest Action

Referred to the House Committee on Financial Services.

March 1, 2023

View full timeline
HouseIntro Referral

Introduced in House

March 1, 2023

HouseIntro Referral

Referred to the House Committee on Financial Services.

March 1, 2023

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued March 1, 2023

I

118th CONGRESS

1st Session

H. R. 1313

IN THE HOUSE OF REPRESENTATIVES

March 1, 2023

Mr. Mooney (for himself, Mr. Posey, Mr. Flood, Mr. Davidson, Mr. Emmer, Mr. Sessions, Mr. Rose, Mr. Ogles, Mr. Nunn of Iowa, Mrs. Kim of California, Mr. Steil, Mr. Williams of Texas, Mr. Fitzgerald, Mr. Huizenga, Mr. Loudermilk, Mr. Luetkemeyer, Mr. Kustoff, Mrs. Houchin, Mr. Barr, and Mr. Norman) introduced the following bill; which was referred to the Committee on Financial Services

A BILL

To enhance rulemaking requirements for the Bureau of Consumer Financial Protection, and for other purposes.

1.

Short title

This Act may be cited as the Transparency in CFPB Cost-Benefit Analysis Act.

2.

Transparency in cost-benefit analysis

Section 1022(b) of the Consumer Financial Protection Act of 2010 (12 U.S.C. 5512(b)) is amended by adding at the end the following:

(5)

Additional rulemaking requirements

(A)

In general

Each notice of proposed rulemaking issued by the Bureau shall be published in its entirety in the Federal Register and shall include—

(i)

a statement of the need for the proposed regulation;

(ii)

an examination of why the Bureau must undertake the proposed regulation and why the private market, State, local, or tribal authorities cannot adequately address the problem;

(iii)

an examination of whether the proposed regulation is duplicative, inconsistent, or incompatible with other Federal regulations and orders;

(iv)

if the proposed regulation is found to be duplicative, inconsistent, or incompatible with other Federal regulations and orders, a discussion of—

(I)

why the proposed regulation is justified;

(II)

how the proposed regulation can coexist with the existing regulations; and

(III)

how the Bureau plans to reduce the regulatory burden associated with the duplicative, inconsistent, or incompatible proposed regulation;

(v)

a quantitative and qualitative assessment of all anticipated direct and indirect costs and benefits of the proposed regulation, including—

(I)

compliance costs for all regulated entities, including small businesses;

(II)

effects on economic activity, efficiency, competition and capital formation;

(III)

regulatory and administrative costs of implementation; and

(IV)

costs imposed on State, local and tribal entities;

(vi)

an identification of reasonable alternatives to the regulation, including modification of an existing regulation;

(vii)

an analysis of the costs and benefits, both quantitative and qualitative, of any alternative identified pursuant to clause (v);

(viii)

if the Bureau determines the proposed regulation would increase costs for small businesses, then the Bureau shall consult the Office of Advocacy within the Small Business Administration to determine ways to minimize the effect of direct and indirect costs imposed on small businesses by the proposed regulation;

(ix)

if quantified net benefits of the proposed action do not outweigh the quantified net benefits of the alternatives, a justification of the regulation;

(x)

if quantified benefits identified pursuant to clause (iv) do not outweigh the quantified costs of the regulation, a justification of the regulation;

(xi)

an assessment of how the burden imposed by the regulation will be distributed; including whether consumers, or small businesses will be disproportionately burdened; and

(xii)

when feasible, and using appropriate statistical techniques, a probability distribution of the relevant outcomes of the proposed regulation.

(B)

Assumptions and studies used

With respect to the information required to be included under subparagraph (A), the Bureau will include—

(i)

a discussion of underlying assumptions used as a basis for such information; and

(ii)

a description of any studies or data used in preparing such information, and whether such studies were peer-reviewed.

.